This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
by Zacks Equity Research
The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.
MMSI's Stock Declines Despite Q3 Earnings Beat, Higher Gross Margin
by Zacks Equity Research
Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the third quarter.
Buy 5 S&P 500 Stocks to Tap Potential Short-Term Price Appreciation
by Nalak Das
These five stocks have provided double-digit returns year to date. Despite the rally, these stocks have double-digit upside potential for the short term. The stocks are: PGR, QCOM, GE, BSX, SPGI.
Top Stock Reports for Amazon.com, Johnson & Johnson and Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Boston Scientific Corporation (BSX), as well as a micro-cap stock Armanino Foods of Distinction, Inc. (AMNF).
Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket
by Zacks Equity Research
TECH registers continued momentum across its Diagnostics & Spatial Biology segment.
DaVita Stock Declines After Q3 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
DVA's robust Dialysis patient service revenues drives its third-quarter performance.
HAE vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
ZBH Stock Up Despite Q3 Earnings Miss, 2024 View Narrowed
by Zacks Equity Research
Zimmer Biomet delivers strong performance across segments and regions in the third quarter of 2024.
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
by Debanjana Dey
ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock
by Zacks Equity Research
Medtronic announces new long-term favorable data for its Symplicity Spyral RDN system, which has undergone a SPYRAL HTN-ON MED clinical trial.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock
by Zacks Equity Research
Abbott initiates the TEAM-HF trial to improve outcomes for advanced heart failure.
Is GMED Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
Globus Medical's synergistic merger with NuVasive and a cadence of product launches bring optimism to investors.
Avantor's Stock Declines Despite Q3 Earnings Beat, Margins Down
by Zacks Equity Research
Despite AVTR's continued stability in the Education and Advanced Technology end markets, it reports an overall soft third-quarter performance.
TFX Stock to Gain From Launch of New Vascular Access Devices in Canada
by Zacks Equity Research
Teleflex launches the next-generation Arrow VPS Rhythm DLX Device and NaviCurve Stylet in Canada.
ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.
ResMed's Stock Rises on Q1 Earnings and Revenue Beat, Margins Expand
by Zacks Equity Research
RMD's stellar first-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls
by Zacks Equity Research
Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.
Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Market Awaits Existing Home Sales Report
by Zacks Equity Research
Market Awaits Existing Home Sales Report.
Pre-Markets Trade Down on Q3 Earnings from Boeing, Coke and More
by Mark Vickery
This morning brings us a good amount of meaningful Q3 results: BA, KO, BSX and NEE.
Compared to Estimates, Boston Scientific (BSX) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Boston Scientific (BSX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 8.62% and 4.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 3 MedTech Stocks Surpass Q3 Earnings Forecasts?
by Urmimala Biswas
Here is a sneak peek into how three MedTech stocks, BSX, TMO and ALGN, are expected to fare in their third-quarter results, slated to be released tomorrow.